Paradox Immunotherapeutics Secures $10 Million Investment from SymBiosis to Advance Therapies for Protein Misfolding Diseases
Funding to accelerate candidates for immunoglobulin light chain amyloidosis and leukocyte chemotactic factor 2 amyloidosis February 25, 2025 08:00 AM Eastern Standard Time TORONTO–(BUSINESS WIRE)–Paradox Immunotherapeutics (“Paradox”), a pharmaceutical company focused on the development of…